PRESTIGE CONSUMER HEALTHCARE INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
PRESTIGE CONSUMER HEALTHCARE INC. (PBH) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $237.06 million for the 12-month period ending 2026-03-31, per its 10-K filed 2026-05-14.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-05-14
- PRESTIGE CONSUMER HEALTHCARE INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2026 was $237.06M, a 5.10% decline from fiscal 2025.
- PRESTIGE CONSUMER HEALTHCARE INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $249.80M, a 4.34% increase from fiscal 2024.
- PRESTIGE CONSUMER HEALTHCARE INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was $239.41M.
- PRESTIGE CONSUMER HEALTHCARE INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$130.33M, a 155.14% decline from fiscal 2022.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2026-03-31 | $237.06M 10-K · filed 2026-05-14 |
| 2025-03-31 | $249.80M 10-K · filed 2026-05-14 |
| 2024-03-31 | $239.41M 10-K · filed 2026-05-14 |
| 2023-03-31 | -$130.33M 10-K · filed 2025-05-09 |
| 2022-03-31 | $236.38M 10-K · filed 2024-05-15 |
| 2021-03-31 | $195.80M 10-K · filed 2023-05-05 |
| 2020-03-31 | $167.51M 10-K · filed 2022-05-06 |
| 2019-03-31 | -$52.31M 10-K · filed 2021-05-07 |
| 2018-03-31 | $84.44M 10-K · filed 2020-05-08 |
| 2017-03-31 | $93.58M 10-K · filed 2019-05-13 |
| 2016-03-31 | $142.25M 10-K · filed 2018-05-10 |
| 2015-03-31 | $122.59M 10-K · filed 2017-05-17 |
| 2014-03-31 | $98.79M 10-K · filed 2016-05-17 |
| 2013-03-31 | $105.73M 10-K · filed 2015-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |